

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

UPDATED INFORMATION ON THE GROUP'S PRODUCT TUL12101 EYE DROPS

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that, on 2 March 2023, the application for the clinical trial of class 1 new drug TUL12101 Eye Drops submitted by Zhuhai United Laboratories Co., Ltd., a wholly-owned subsidiary of the Company, was approved by China National Medical Products Administration, with reference numbers of CXHL2200843, CXHL2200844 and CXHL2200845.

TUL12101 is a new generation of small molecule RASP (Reactive Aldehyde Specie) inhibitor developed by the Company for the treatment of dry eye syndrome. RASP is a pro-cytokine mediator of inflammation. By binding to thiol and amine residues on proteins, it enhances the release of cytokines and activates inflammasomes, and it can also bind to class A scavenger receptors (SR-A1/CD204) to produce pro-inflammatory effects. As a RASP inhibitor, TUL12101 can covalently bind free aldehydes and reduce excessive RASP levels, rapidly reduce the content of active aldehydes in the eye, relieve inflammation and break the vicious cycle of inflammation, thereby achieving the purpose of treating dry eye syndrome. At present, there are no other products with the same mechanism on the market in China or abroad.

This approval further enriched the Company's ophthalmic product pipeline and helped to enhance the Company's market competitiveness in the field of ophthalmic drugs. In future, the Company will continue to devote itself to the research and development of new products, which is expected to create more benefits for the Company and its shareholders.

By Order of the Board

The United Laboratories International Holdings Limited

Tsoi Hoi Shan

Chairman

Hong Kong, 3 March 2023

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.